Product Description
Alpha1 Proteinase Inhibitor for Cystic Fibrosis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01347190)
Mechanisms of Action: PDGF Blocker
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CSL Behring
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: alpha 1-Antitrypsin Deficiency|Cystic Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CR002_1004 | P1 |
Completed |
alpha 1-Antitrypsin Deficiency|Cystic Fibrosis |
2011-08-01 |